Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.38 |
| ▸ | F3 | P13726 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29499512 | 1.00 | HDAC8 (0.44) | HDAC8HDAC1HDAC2HDAC3HDAC6 | |
| SCHEMBL22698990 | 0.77 | PTGS2 (0.56) | HDAC8HDAC1HDAC2HDAC3HDAC6 | |
| SCHEMBL17823121 | 0.77 | TP53 (0.41) | HDAC1HDAC2CA12CA1CA2 | |
| SCHEMBL15703641 | 0.77 | TP53 (0.41) | HDAC1HDAC2CA12CA1CA2 | |
| SCHEMBL15496084 | 0.77 | TBXAS1 (0.44) | HDAC8HDAC1HDAC2HDAC3HDAC6 | |
| SCHEMBL28960892 | 0.76 | HDAC8 (0.46) | HDAC8HDAC1HDAC2HDAC3HDAC6 | |
| SCHEMBL4275813 | 0.76 | ADAMTS4 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL4275810 | 0.76 | ADAMTS4 (0.43) | CA12CA1CA2CA9CA14 | |
| SCHEMBL20542578 | 0.75 | TDP1 (0.52) | HDAC8HDAC1HDAC2HDAC3HDAC6 | |
| SCHEMBL904391 | 0.74 | PLG (0.47) | HDAC3HDAC6CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4651903-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651904-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF AUTOANTIBODIES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651901-A1 | CYCLING LYSOSOMAL TARGETING ANTIBODY CONJUGATES | Lycia Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. | 2025-04-24 | — | — | US | disclosed |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | LYCIA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| WO-2025035040-A1 | LYSOSOMAL TARGETING BIFUNCTIONAL MOLECULES FOR DEGRADATION OF MUSCLE-SPECIFIC KINASE AUTOANTIBODIES | LYCIA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-4490168-A1 | CTLA-4 BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND USES THEREOF | Molecular Templates, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240335544-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024155748-A1 | M6PR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2022197945-A1 | PD-L1 BINDING PROTEINS COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS AND CD8+ T CELL ANTIGENS | MOLECULAR TEMPLATES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-4031576-A1 | PD-L1 BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS | Molecular Templates, Inc. (US) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022150721-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | LYCIA THERAPEUTICS, INC. (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-114423793-A | PD-L1 binding molecules comprising Shiga toxin A subunit scaffolds | 分子模板公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2021263061-A2 | MODIFIED VIRAL COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| WO-2021263060-A2 | BIFUNCTIONAL BRIDGING COMPOSITIONS FOR VIRAL TRANSDUCTION | LYCIA THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| US-11136395-B2 | PD-L1 -binding molecules comprising Shiga toxin A subunit scaffolds | MOLECULAR TEMPLATES, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| WO-2021055816-A1 | PD-L1 BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS | MOLECULAR TEMPLATES, INC. (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20210079097-A1 | PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-03-18 | — | — | US | disclosed |
| US-20210079098-A1 | PD-L1-BINDING MOLECULES COMPRISING SHIGA TOXIN A SUBUNIT SCAFFOLDS | ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240335544-A1 | M6PR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | M6PR, IGF2R, ASGR1 | HDAC8 2770/4885HDAC1 3292/4885HDAC2 3692/4885 |
| US-12258332-B2 | ASGPR cell surface receptor binding compounds and conjugates | ASGR1, LAMP2, FCGR2A | HDAC8 1457/4885HDAC1 3235/4885HDAC2 2809/4885 |
| US-20250127913-A1 | BIFUNCTIONAL FOLATE RECEPTOR BINDING COMPOUNDS | FOLR1, FOLR2, FOLH1 | HDAC8 2734/4885HDAC1 4074/4885HDAC2 4499/4885 |
| US-20250101007-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | HDAC8 1457/4885HDAC1 3235/4885HDAC2 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.